Survival Benefits with Keytruda and Padcev in Advanced Urothelial Cancer
Patients with previously untreated locally advanced or metastatic urothelial carcinoma experienced favorable progression-free survival, overall survival and objective response rates when treated with Padcev and Keytruda versus chemotherapy.
Source: curetoday.com